Insmed CEO Will Lewis appeared on CNBC’s Fast Money to provide an update on the company’s rare disease drug candidates and discuss strategic acquisitions. Lewis highlighted the recent FDA approval of Brinsupri for pulmonary alveolar proteinosis, which has already treated over 1,200 patients since its Q1 2025 launch. He noted two supplemental biologics license applications for expanded indications are slated for FDA submission in mid-2026. On the acquisition front, Lewis emphasized Insmed’s focus on bolt-on deals in the $50 million to $150 million range, targeting complementary programs in lysosomal storage disorders. He disclosed that the company is in active discussions with three privately held biotech firms, any of which could close by year-end, bolstering Insmed’s pipeline depth without dilutive capital raises.

Preliminary full-year 2025 results show Insmed generated approximately $260 million in global Brinsupri sales, surpassing the company’s original $230 million to $250 million forecast. Strong patient demand in North America and the EU drove a 35% quarter-over-quarter uptake in Q4, as managed‐care coverage expanded to 85% of targeted providers. For 2026, Insmed projects Brinsupri sales of $400 million to $450 million, supported by planned label expansions and launch in Japan. The company also reaffirmed its goal to file three new investigational new drug applications, including one for a next-generation enzyme replacement therapy in Gaucher disease, with topline data expected in H2 2026.